Zosano Pharma Corp (NASDAQ:ZSAN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price objective of $4.00 for the company and are forecasting that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Zosano Pharma an industry rank of 98 out of 265 based on the ratings given to related companies.
Separately, ValuEngine upgraded Zosano Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
Zosano Pharma (NASDAQ:ZSAN) traded down $0.03 during trading hours on Friday, reaching $0.60. The company had a trading volume of 521,299 shares, compared to its average volume of 1,504,313. Zosano Pharma has a 12-month low of $0.56 and a 12-month high of $3.54.
Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). analysts expect that Zosano Pharma will post -0.79 EPS for the current fiscal year.
In other Zosano Pharma news, Director Kenneth Greathouse acquired 50,000 shares of Zosano Pharma stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $0.62 per share, with a total value of $31,000.00. Following the completion of the transaction, the director now owns 35,000 shares of the company’s stock, valued at $21,700. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.95% of the company’s stock.
An institutional investor recently raised its position in Zosano Pharma stock. Northern Trust Corp raised its stake in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,234 shares of the biotechnology company’s stock after acquiring an additional 67,774 shares during the quarter. Northern Trust Corp owned approximately 0.20% of Zosano Pharma worth $112,000 as of its most recent filing with the SEC. 19.68% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/12/06/zosano-pharma-corp-zsan-given-4-00-average-price-target-by-analysts.html.
Zosano Pharma Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.